Your patient is experiencing bronchospasm secondary to asthma and is unresponsive to bronchodilator therapy. Her current medications include propafenone, lidocaine, and albuterol. Which of these medications could be contributing to her unresponsiveness to
a. Propafenone
b. Lidocaine
c. Albuterol
d. None could cause this unresponsiveness
Q. 2 Implantable cardioverter-defibrillators (ICDs) are indicated for the following conditions: 1. Cardiac arrest caused by pulseless ventricular tachycardia (VT) 2. Spontaneous sustained VT
3. Asystole
4. Pulseless electrical activity
5. Electrophysiologically inducible VT or ventricular fibrillation (VF) not suppressed by class I antiarrhythmics
a. 1 only
b. 1, 2, and 5 only
c. 1, 2, 3, and 4 only
d. 1, 2, 3, 4, 5
Q. 3 When should intravenous access and medication be considered during pulseless ventricular tachycardia?
a. After beginning cardiopulmonary resuscitation (CPR) and attempting defibrillation
b. Before beginning CPR and attempting defibrillation
c. When the patient has an established advanced airway
d. Intravenous access and medication are not a part of the treatment algorithm for pulseless ventricular tachycardia
Q. 4 Ablation with radiofrequency current is effective in the treatment of
a. atrial fibrillation (AF) caused by multiple circuits.
b. asystole.
c. sinus rhythm.
d. AF caused by single primary circuit.
Q. 5 Place the five phases of a myocardial action potential in correct order. 1. Fast sodium channels are inactivated 2. Cell returns to its resting state 3. Plateau phase 4. Initial rapid depolarization of myocardial tissues 5. Calcium channels close
a. 1, 3, 2, 5, 4
b. 4, 1, 3, 5, 2
c. 1, 2, 3, 4, 5
d. 4, 1, 2, 5, 3
Q. 6 Digoxin toxicity may include which of the following manifestations? 1. Hyperkalemia 2. Premature ventricular contractions 3. Bigeminal rhythm 4. Nausea 5. Abdominal pain
a. 2 and 5 only
b. 1, 2, and 3 only
c. 1, 2, 3, 4, and 5
d. 1, 2, 3, and 5 only